Interferon and murine leukemia. VII. Therapeutic effect of interferon preparations after diagnosis of lymphoma in akr mice

Gresser, Ion; Maury, Chantal; Tovey, Michaël G.

doi:10.1002/ijc.2910170514

Cited by 51 publications

(12 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This dose was selected based on the data from the initial Mayo Clinic Phase I trial. 16 However, because no significant hematologic toxicity occurred in the first 10 patients treated at this dose level, the dose of doxorubicin was increased to 35 mg/m2 for 6 patients and then to 40 mg/m2 for the remaining 15. The maximum allowable total dose for doxorubicin was 500 mg/m2.…”

Section: Methodsmentioning

confidence: 99%

Combined doxorubicin and alpha-interferon therapy of advanced hepatocellular carcinoma

Kardinal

Moertel

Wieand

et al. 1993

Cancer

View full text Add to dashboard Cite

Background. Modest activity for doxorubicin has been detected repeatedly for the therapy of advanced hepatocellular carcinoma. Variable activity in this disease also has been documented for alpha‐interferon. Preclinical data indicated the possibility that alpha‐interferon could enhance or add to the cytotoxic effect of doxorubicin. Methods. The authors evaluated the use of alpha‐interferon at a dose of 12 × 106 units/m2/day for 5 days given by intramuscular injection plus doxorubicin 25–40 mg/m2 given intravenously on day 3 (both repeated every 4 weeks) for the treatment of advanced hepatocellular carcinoma. Results. Among 31 eligible patients treated, there was only one instance of objective tumor regression. The median survival for all patients was 10 months. Both hematologic and nonhematologic toxicity were significant but tolerable to the patients. Conclusions. The 3% response rate indicated that, by the method used, the addition of alpha‐interferon to doxorubicin does not improve the clinical effectiveness. This combination cannot be recommended for further study.

show abstract

Section: Methodsmentioning

confidence: 99%

Combined doxorubicin and alpha-interferon therapy of advanced hepatocellular carcinoma

Kardinal

Moertel

Wieand

et al. 1993

Cancer

View full text Add to dashboard Cite

show abstract

“…injection of interferon for 3 weeks in normal mice did not induce any necrosis of normal adult host tissues (data not shown). It should be recalled, however, that daily interferon treatment of newborn mice induced a massive liver-cell necrosis (Gresser et al, 1975(Gresser et al, , 1981. Pathological examination of the livers of these mice also suggested a diagnosis of "ischemic necrosis" although the vascular system was found to be normal (Gresser et al, 1981).…”

Section: Histology Of Flc Tumors In Mice Injected With Highly Purifiementioning

confidence: 99%

Antitumor effects of interferon in mice injected with interferon‐sensitive and interferon‐resistant friend leukemia cells. III. Inhibition of growth and necrosis of tumors implanted subcutaneously

Belardelli

Gresser

Maury

et al. 1983

Intl Journal of Cancer

View full text Add to dashboard Cite

Administration of highly purified interferon to DBA/2 mice inhibited the growth of interferon-sensitive or interferon-resistant Friend erythroleukemia cells implanted subcutaneously. Injection of interferon at the site of tumor inoculation was more effective than injection of interferon intraperitoneally. Histologic examination of tumors in interferon-treated mice showed extensive areas of tumor-cell necrosis in the absence of an obvious host-cell infiltrate. Interferon inhibited the growth of established subcutaneous tumors and induced complete tumor regression in some mice. Interferon treatment also resulted in an inhibition of tumor metastases in the liver and spleen.

show abstract

“…There fore, the treatment with PTZ in this report could be designated as mainly therapeutic rather than prophylactic for the groups but not for the individuals. In addition to the prophylactic treatment with such high mo lecular immunomodulators as BCG, OK-432, Poly A:U and neuraminadase-treated leukemia cells [2] or purified mouse inter feron [2,11], several cytotoxic chemicals and their combinations have been reported to be effective against AKR spontaneous leukemia [2,10,17,18]. Cyclophospham ide was found to be one of the most active agents among the low molecular substances [10,17,18] which generally have more ad vantages as therapeutical drugs in com parison to high molecular agents.…”

Section: Discussionmentioning

confidence: 99%

Therapeutic Activity of Pretazettine, a Narcissus Alkaloid, on Spontaneous AKR Leukemia

Furusawa¹,

Lockwood²,

Furusawa³

et al. 1979

Chemotherapy

View full text Add to dashboard Cite

A narcissus alkaloid, pretazettine hydrochloride (PTZ) has been shown to be active against spontaneous AKR leukemia. The long-term treatment with PTZ begining at 5–7 months of age of a group of AKR mice containing 10–20% of advanced leuke-mic mice significantly prolonged the life span of the group. The therapeutic effectiveness of PTZ has been compared with several standard antileukemic drugs. PTZ decreased the AKR virus titer in the circulating blood of mice and its antiviral activity in AKR virus infected NIH/3T3 cells has been confirmed by XC assay.

show abstract

Interferon and murine leukemia. VII. Therapeutic effect of interferon preparations after diagnosis of lymphoma in akr mice

Cited by 51 publications

References 14 publications

Combined doxorubicin and alpha-interferon therapy of advanced hepatocellular carcinoma

Combined doxorubicin and alpha-interferon therapy of advanced hepatocellular carcinoma

Antitumor effects of interferon in mice injected with interferon‐sensitive and interferon‐resistant friend leukemia cells. III. Inhibition of growth and necrosis of tumors implanted subcutaneously

Therapeutic Activity of Pretazettine, a Narcissus Alkaloid, on Spontaneous AKR Leukemia

Contact Info

Product

Resources

About